Review article · 2014 · Open access

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options

Pierre S. Chue, Justine K. Lalonde

Neuropsychiatric Disease and Treatment, 10, 777 · Published 1 May 2014 · DOI 10.2147/ndt.s43404

Open PDFView at the publisherCite this paper

In brief

“Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options” is a 2014 review article by Pierre S. Chue and Justine K. Lalonde, published in Neuropsychiatric Disease and Treatment. OpenAlex counts 87 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Neuropsychiatric Disease and Treatment.

Citations
87
Most cited in
2016 (12)
Field-weighted impact
1.59
References
121
Authors
2

Abstract

The negative symptoms of schizophrenia represent an impairment of normal emotional responses, thought processes and behaviors, and include blunting or flattening of affect, alogia/aprosody, avolition/apathy, anhedonia, and asociality. Negative symptoms contribute to a reduced quality of life, increased functional disability, increased burden of illness, and poorer long-term outcomes, to a greater degree than positive symptoms. Primary negative symptoms are prominent and persistent in up to 26% of patients with schizophrenia, and they are estimated to occur in up to 58% of outpatients at any given time. Negative symptoms respond less well to medications than positive symptoms, and to date treatment options for negative symptoms have been limited, with no accepted standard treatment. Modest benefits have been reported with a variety of different agents, including second-generation antipsychotics and add-on therapy with antidepressants and other pharmacological classes. Recent clinical research focusing on negative symptoms target novel biological systems, such as glutamatergic neurotransmission. Different approaches include: enhancing N-methyl-D-aspartate receptor function with agents that bind directly to the glycine ligand site or with glycine reuptake inhibitors; influencing the metabotropic glutamate receptor (mGluR2/3) with positive allosteric modulators; and stimulating nicotinic acetylcholine receptors. In conclusion, the lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes. Hence, further research to identify and characterize novel pharmacological treatments for negative symptoms is greatly needed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chue, P. S., & Lalonde, J. K. (2014). Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment, 10, 777. https://doi.org/10.2147/ndt.s43404

MLA 9

Chue, Pierre S., and Justine K. Lalonde. “Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.” Neuropsychiatric Disease and Treatment, vol. 10, 2014, p. 777. https://doi.org/10.2147/ndt.s43404.

Chicago

Chue, Pierre S. and Justine K. Lalonde. 2014. “Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.” Neuropsychiatric Disease and Treatment 10: 777. https://doi.org/10.2147/ndt.s43404.

Harvard

Chue, P. S. and Lalonde, J. K. (2014) ‘Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options’, Neuropsychiatric Disease and Treatment, 10, p. 777. doi:10.2147/ndt.s43404.

IEEE

P. S. Chue and J. K. Lalonde, “Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options,” Neuropsychiatric Disease and Treatment, vol. 10, p. 777, 2014, doi: 10.2147/ndt.s43404.

BibTeX

@article{chue2014addressing,
  title     = {{Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options}},
  author    = {Chue, Pierre S. and Lalonde, Justine K.},
  journal   = {Neuropsychiatric Disease and Treatment},
  year      = {2014},
  volume    = {10},
  pages     = {777},
  doi       = {10.2147/ndt.s43404},
  url       = {https://doi.org/10.2147/ndt.s43404}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20161212
20171212
20181010
201977
202077
202199
202233
202311
202511
202622

Its field-weighted citation impact is 1.59: it has been cited 1.59 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • schizophrenia
  • negative symptoms
  • unmet medical needs
  • pharmacotherapy
  • NMDA receptor agonist
  • mGluR2/3
  • positive allosteric modulators
  • nicotinic acetylcholine receptors

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Chue, P. S., & Lalonde, J. K. (2014). Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment, 10, 777. https://doi.org/10.2147/ndt.s43404

How many times has this paper been cited?

87 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Neuropsychiatric Disease and Treatment: sign in and open the PDF from this page.

Who wrote this paper?

Pierre S. Chue, Justine K. Lalonde.

What is the DOI of this paper?

10.2147/ndt.s43404, permanently at https://doi.org/10.2147/ndt.s43404. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.